European regulators find no evidence of link between new obesity medicines and suicidal thoughts
LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.
The announcement from the European Medicines Agency echoes the findings of a review by the U.S. Food and Drug Administration, which in January said it did not find a causal relationship between the class of weight loss and diabetes medications and suicidal ideation.
